Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
Department of Pediatrics, National Taiwan University Children's Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
J Microbiol Immunol Infect. 2023 Jun;56(3):433-441. doi: 10.1016/j.jmii.2023.04.001. Epub 2023 Apr 6.
From January 2020 to December 2022, there was a total of 8,872,955 confirmed COVID-19 cases in Taiwan. In addition, a total of 15,253 COVID-19 related deaths were reported. During these three years, the government and health authority did many efforts to response this pandemic. In the early pandemic, Taiwan Central Epidemic Command Center was established in the early 2020 to organize associated resource, develop effective policy and implement strict intervention. In response to COVID-19 pandemic, many infection control policy and interventions, including universal mask wearing with increasing production of face mask, hand hygiene, border control, introduce of digital technology incorporating big data, quarantine of COVID-19 cases, travel and gathering restriction, were implemented. In the meanwhile, two COVID-19 vaccines, namely MVC-COV1901 and UB-612, have been developed under the support of government. Furthermore, MVC-COV1901 was taken into clinical practice after received emergency use approval. In addition, two traditional Chinese medicines, including NRICM101 and NRICM102 showed their promising effect against SARS-CoV-2 infection and were recommended as potential therapeutic options for COVID-19. During the pandemic, the nonpharmacologic intervention help reduce many infectious diseases, especially for airborne/droplet-transmitted diseases. However, COVID-19 exhibited some adverse impacts on the healthcare systems, such as emergency medical service on out of hospital cardiac arrest, cancer screening, HIV screening and prevention services, and public health, namely the psychosocial status of healthcare workers. Although the outbreak of SARS-CoV-2 infections may gradually subsided, we should keep monitoring its associated impact and appropriately response to this pandemic.
从 2020 年 1 月至 2022 年 12 月,台湾共有 8872955 例确诊 COVID-19 病例。此外,共报告了 15253 例与 COVID-19 相关的死亡病例。在这三年中,政府和卫生当局为应对这一大流行病做出了许多努力。在大流行早期,台湾中央流行疫情指挥中心于 2020 年初成立,以组织相关资源,制定有效政策并实施严格干预。针对 COVID-19 大流行,实施了许多感染控制政策和干预措施,包括全民佩戴口罩(随着口罩产量的增加)、手部卫生、边境管控、引入大数据数字技术、隔离 COVID-19 病例、旅行和聚会限制。与此同时,在政府的支持下,开发了两种 COVID-19 疫苗,即 MVC-COV1901 和 UB-612。此外,在获得紧急使用批准后,MVC-COV1901 已投入临床实践。此外,两种中药,包括 NRICM101 和 NRICM102,显示出对 SARS-CoV-2 感染的有希望的效果,并被推荐为 COVID-19 的潜在治疗选择。在大流行期间,非药物干预有助于减少许多传染病,特别是空气传播/飞沫传播疾病。然而,COVID-19 对医疗保健系统产生了一些不利影响,例如院外心脏骤停、癌症筛查、艾滋病毒筛查和预防服务以及公共卫生(即医护人员的心理社会状况)的紧急医疗服务。虽然 SARS-CoV-2 感染的爆发可能逐渐减弱,但我们仍应继续监测其相关影响,并对这一大流行病做出适当反应。